hrp0086rfc8.3 | Growth: Clinical | ESPE2016

Batch-to-Batch Consistency of a Highly O-Glycosylated Long-Acting Human Growth Hormone (MOD-4023)

Moschcovich Laura , Guy Rachel , Felikman Yana , Zakar Miri , Hershkovitz Oren

Background: OPKO Biologics is a clinical-stage public company developing long-acting therapeutic proteins utilizing CTP technology. The technology involves fusion of the C-terminal peptide of human chorionic gonadotropin (hCG), which is highly O-glycosylated, to the target protein. CTP enabled the production of a long-acting human growth hormone (hGH) (MOD-4023), which supports a single weekly injection in growth hormone-deficient patients. MOD-4023 is manufactured as a non-vi...

hrp0086p1-p615 | Growth P1 | ESPE2016

Immunogenicity Results of Once-Weekly Administration of CTP-Modified Human Growth Hormone (MOD-4023): A Phase 2 Study in Children with Growth Hormone Deficiency

Mendelson Michal Jaron , Bar-Ilan Ahuva , Hershkovitz Oren , Hart Gili

Background: CTP-modified hGH (MOD-4023) has been developed for once weekly administration in GH deficient (GHD) adults and children. Immunogenicity samples of once-weekly s.c. administration of MOD-4023 were detected for the presence of binding and neutralizing anti-MOD-4023 Ab’s in pediatric Phase 2 study.Objective and hypotheses: During the first year of the study, 53 pre-pubertal GHD children were treated with once-weekly s.c. injections of one o...

hrp0084fc7.5 | Growth-promoting therapies | ESPE2015

12-Month Safety and Efficacy of a Weekly Long-Acting GH (MOD-4023) Compared to Daily Recombinant Human GH Therapy in Pre-Pubertal GH-Deficient Children; Phase 2 Study: Study CP-4-004 Summary

Zadik Zvi , Rosenfeld Ron , Radziuk Klaudziya , Zelinska Nataliya , Malievsky Oleg , Iotova Violeta , Skorodok Julia , Koren Ronit , Amitzi Leanne , Hershkovitz Oren , Hart Gili

Objective and hypotheses: To compare the PK/PD, safety, efficacy, and tolerability of three doses of once-weekly MOD-4023 to that of a daily recombinant human GH (rhGH) formulation in pre-pubertal children with growth failure due to GH deficiency (GHD).Method: The randomised, controlled phase 2 study was conducted in 53 pre-pubertal, hGH-naïve GHD children randomised to receive one of three MOD-4023 doses as a once-weekly s.c. injection (0.25, 0.48,...

hrp0082p1-d3-164 | Growth (2) | ESPE2014

Characterization of MOD-4023 Glycosylation, a CTP Modified Long Acting GH in Advanced Clinical Stages

Herskovitz Oren , Moschovich Laura , Guy Rachel , Felikman Yana , Fima Eyal

Background: Prolor Biotech, Inc. is a clinical stage public company developing long acting therapeutic proteins utilizing a technology called CTP. The technology involves fusion of the C-terminus peptide of hCG, which is a highly O-glycosylated peptide, to the target protein. Manufacturing process was developed to generate a reproducible highly glycosylated CTP-modified long-acting hGH (MOD-4023), which supports a single weekly injection in GH deficient patients. MOD-...

hrp0082fclb1 | Late Breaking Abstracts | ESPE2014

Top Line Results of Once-Weekly, CTP-Modified Human GH (MOD-4023): Phase 2 Dose Finding Study in Children with GH Deficiency

Zadik Zvi , Rosenfeld Ron , Radziuk Klaudziya , Zelinska Nataliya , Malievsky Oleg , Iotova Violeta , Skorodok Julia , Koren Ronit , Amitzi Leanne , Hart Gili , Herskovitz Oren , Fima Eyal

Objective: GH replacement therapy currently requires daily injections, which may cause poor compliance, inconvenience and distress for patients. CTP-modified hGH (MOD-4023) has been developed for once-weekly administration in GH deficient (GHD) adults and children. Pharmacokinetics (PK), pharmacodynamics, (PD) efficacy and safety analysis of weekly treatment with MOD-4023 in GHD naïve children was performed and compared to daily hGH.Design and metho...

hrp0089fc10.6 | Late Breaking | ESPE2018

Primary Ovarian Insufficiency Incidence Rate and ETIOLOGY AMONG ISRAELI ADOLESCENTS between the Years 2000–2016 – A Multi-Center Study

Gruber Noah , Kugler Shir , de Vries Liat , Brener Avivit , Zung Amnon , Eyal Ori , Rachmiel Marianna , Koren Ilana , Tenenbaum-Rakover Yardena , Hershkovitz Eli , Landau Zohar , Oren Meirav , Eliakim Alon , Zangen David , German Alina , Majdoub Hussein , Mazor-Aronovitch Kineret , Modan-Moses Dalit , Yeshayahu Yonatan , Naugolni Larisa , Levy-Shraga Yael , Ben-Ami Michal , Brill Gherta , Levy-Khademi Floris , Avnon-Ziv Carmit , Tiosano Dov , Harel Shira , Kedem Einat , Segev-Becker Anat , Shoenfeld Yehuda , Pinhas-Hamiel Orit

Introduction: Primary ovarian Insufficiency (POI) occurring in youth is a devastating condition. POI is characterized by at least 4 months of disordered menses in association with menopausal follicle stimulating hormone (FSH) levels. The most common causes of POI in adolescence are iatrogenic and chromosomal abnormalities. Data are scarce regarding the incidence of POI in adolescents.Objectives: We aimed to estimate the incidence and the distribution of ...

hrp0084p2-390 | Fat | ESPE2015

Programming of Rat Behaviours and the Stress Response by Duration of the Infancy Stage

Crispel Yonatan , Katz Oren , Hochberg Ze'ev

Background: The age at weaning programs life history adaptively. Shorter infancy resulted in longer/thinner animals with a reproductive-strategic shift to earlier physical and sexual development (BMC Med, 2013).Hypotheses: The length of infancy impacts also the stress-response and has behavioural consequences.Method: Sprague-Dawley pups (generation F1), which usually are weaned at age 21 days, were weaned by cross-fostering at age ...

hrp0084fc14.3 | Puberty | ESPE2015

The New Syndrome of Hypogonadotropic Hypogonadism, Arrythmogenic Right Ventricular Dysplasia, Facial Dysmorphism and Absence of Corpus Callosum is Associated to TAX1 Binding Protein 3 Gene Mutation

Hershkovitz Eli , Arafat Maram , Afawi Zaid , Loewenthal Neta , Haim Alon , Levitas Aviva , Parvari Ruti

Background: A growing list of genes has been implicated in the pathogenesis of congenital hypogonadotropic hypogonadism (HH).Objective and hypotheses: To identify the cause of a unique syndromic HH in a consanguineous Bedouin family.Method: Medical records of the patients were reviewed. Genotyping of the brothers and their parents and whole exome sequencing (WES) were performed.Results: Two brothers presented...

hrp0092p1-32 | Diabetes and Insulin | ESPE2019

Heterozygous RFX6 Mutation as a Cause of Diabetes Mellitus in a Multigenerational Family

Zuckerman Levin Nehama , Paperna Tamar , Hershkovitz Tova , Mory Adi , Kurolap Alina , Mahameed Jamal , Feldman Hagit Baris , Shehadeh Naim

Background: Monogenic diabetes mellitus (DM) is an early-onset, non- autoimmune diabetes. Genetic diagnosis can personalize patient management and lead to prevention. We describe four generations of DM in one family, caused by a heterozygous mutation in the RFX6 gene. RFX6 (Regulatory factor X, 6) is essential for the development of the endocrine pancreas. Mutations in RFX6 can cause neonatal (Mitchell-Riley syndrome) as well as childhood DM,...

hrp0095p1-145 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Spatial navigation and memory in transgender male adolescents treated with gender affirming hormones

Perl Liat , Oren Asaf , C. Mueller Sven , Raphael Ido , Borger Ophir , Sheppes Tamar , Shechner Tomer

Background: Spatial navigation is an essential human skill that helps individuals track their changes in position and orientation by integrating self-motion cues. Meta-analyses indicate that males, on average, perform better than females on a number of spatial tasks. Sex steroids, mainly androgens, modulate the remodeling of synapses in the prefrontal cortex and hippocampus, a limbic brain area with critical influence on spatial and contextual memory. Androgen...